FDA 483 - JMA Partners - April 20, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Guardian Pharmacy Services in Dallas, TX, a producer of sterile and non-sterile drug products, was conducted from April 2-20, 2018. The inspection revealed 15 observations regarding deficiencies in their manufacturing and quality control systems.
Key observations include: - **Environmental Monitoring:** Aseptic processing areas lacked adequate environmental monitoring. Personnel and ISO 5 surface sampling, required monthly, had not been conducted since December 28, 2017. Semi-annual recertification of ISO 5 hoods, ISO 7 buffer room, and ISO 8 anteroom had not occurred since June 28, 2017. This was a repeat observation. - **Cleaning and Disinfection:** Deficiencies were noted in the system for cleaning and disinfecting aseptic processing areas and equipment. Cleaning records from January 1, 2018, through April 13, 2018, were unavailable. - **Air Recirculation:** Air was recirculated to production areas without adequate dust control. Air visualization pattern testing (smoke studies) for ISO 5 laminar airflow hoods was not documented to ensure unidirectional airflow and proper air recirculation. - **Equipment Design and Maintenance:** An ISO 5 laminar airflow workbench had a non-stainless steel work surface bordered with non-porous particle board, which was not easily cleanable and a potential source of contamination. This was a repeat observation.
ID · d4151ad6-01a4-4c23-af0f-9ff5f1a54e27
Full citation text and observation details available on the Dashboard.